Bioelectronic Medicine · Cardiovascular Health
Reimagining the Future of Cardiovascular Health.
Afferent Medical Solutions is developing a novel algorithm of non-invasive, device-based neuromodulation for the treatment of hypertension and other cardiovascular diseases.

Conceptual prototype mock-up | Technology under development
FEATURED IN THE MEDIA


Bioelectronic Medicine · Hypertension
-12.7 mmHg*
A signal in participants with higher baseline blood pressure.
* Treatment difference versus sham in the prespecified subgroup with baseline daytime systolic blood pressure ≥160 mmHg.
OUR FOCUS
Neuromodulation for cardiovascular diseases
Device-based approaches developed from decades of basic science research
OUR APPROACH
Non-invasive and designed for home use
AffeX technology is a device designed for a guided treatment session.
OUR WORK
Research, technology and patient support
Clinical evidence and connected-care tools are being developed together.
WHO WE ARE
Improving Human Health Through Research and Technology.
Afferent is a bioelectronic medicine company founded on decades of academic neuroscience research. The company was established to develop and commercialise advances in device-based neuromodulation for diseases of the circulatory system and other therapeutic areas where existing pharmacological treatments remain inadequate.
​
Afferent is a UK-based medical technology company bringing together scientific, clinical and engineering expertise to develop and commercialise innovative neuromodulation therapies.
​
OUR TECHNOLOGY
One Connected Approach, from Device to Care Team.
AffeX and AffeX+ are being developed to bring together the treatment device, patient support and clinician oversight.

THE DEVICE
AffeX
AffeX technology delivers a programmed session of transcutaneous auricular stimulation.
​

CONNECTED CARE
AffeX+
Digital platform connects patients and healthcare professionals with treatment information and remote support.
​

PATIENT CARE
Designed around daily use
The treatment is intended to fit into a simple home routine, with a typical session lasting 30 minutes during treatment course.
​
Conceptual prototype mock-up

Conceptual prototype mock-up | Technology under development
DIGITAL SUPPORT
Turning Daily Readings Into a Clearer Picture.
AffeX+ is an integrated digital health platform currently under development, being designed to connect patients and healthcare professionals within a unified treatment management ecosystem. The platform will combine remote patient monitoring, treatment adherence tracking and clinical decision support to facilitate personalised therapy and continuous clinical oversight.
​

PERSONALISED
Identifying Responders with AI
Afferent is developing an AI-powered predictive model to identify patients most likely to benefit from tanX therapy. By integrating cardiovascular, physiological and clinical data, the system predicts individual treatment responsiveness and anticipated therapeutic efficacy, supporting a personalised approach to hypertension management.
​​
“Our non-invasive device-based technology is truly a game changer that has the potential to improve the health of millions of hypertensive patients.”
Prof. K. Michael Spyer · Chair at Afferent · Ex-Chair NHS London
BASED IN THE UK
Bringing Research and Technology Together
Afferent Medical Solutions is a UK-based, privately funded bioelectronics medicine company.
​
